OBJECTIVES: Cardiac ischaemic marker release is associated with adverse clinical outcomes after cardiac surgery. We sought to compare the release of cardiac troponin I (cTnI) after hybrid coronary revascularization (HCR) with off-pump coronary artery bypass surgery (OPCAB).
INTRODUCTION
Although coronary revascularization improves outcomes in selected patients with coronary artery disease (CAD), these procedures may themselves also cause myocardial tissue damage. Detection of elevated cardiac biomarkers provides a high accuracy in the detection of irreversible myocardial injury, and they have been associated with an incrementally increased mortality risk following both surgical and percutaneous revascularization [1] [2] [3] . The causes of myocardial ischaemia and necrosis during surgery may be iatrogenic trauma due to manipulation or inadequate myocardial protection, cardioplegia, incomplete revascularization, reperfusion injury, hypotension, bleeding, ventricular arrhythmias and acute bypass graft closure [4] [5] [6] . Hybrid coronary revascularization (HCR) has emerged as an alternative revascularization approach that combines surgical and percutaneous techniques to provide complete coronary revascularization in patients with multivessel CAD. It is unknown whether the release of cardiac ischaemic markers is similar following HCR compared with coronary artery bypass grafting (CABG) surgery, or whether this may affect outcomes. We, therefore, conducted a retrospective analysis using data from a prospective single-centre registry.
MATERIALS AND METHODS

Study population and data collection
The study population of the current analysis was derived from a prospective single-centre patient cohort that underwent either HCR or off-pump coronary artery bypass surgery (OPCAB) between September 2008 and September 2012. Consecutive patients were included in this registry, when they met the following criteria: CAD that involved at least two major coronary arteries with >50% stenosis, and were symptomatic or asymptomatic with an abnormal stress test. Candidates for HCR also met the following angiographic criteria: (i) left anterior descending artery (LAD) and/or diagonal disease that was not amenable to percutaneous coronary intervention (PCI), but suitable for bypass surgery, and non-LAD disease that was amenable to PCI or bypass surgery; or (ii) left main disease with LAD and/or diagonal suitable for bypass surgery and left circumflex artery (LCx) and/or RCA disease amenable to PCI and bypass surgery. Patients with elevated baseline cardiac markers, haemodynamically unstable with a need for emergent CABG, or SYNTAX scores [7] above 60 were excluded. The same surgeons performed HCR and OPCAB procedures. Clinical characteristics, preoperative risk factors, medications, angiographic and procedural data, laboratory results and in-hospital events were monitored by research personnel and recorded in an electronic database. Baseline characteristics were defined according to the STS Adult Cardiac Database data specification criteria (http:// www.sts.org/national-database). Patient mortality risk scores were calculated using the EuroSCORE and predicted risk of mortality score [8] .
Procedures
Surgical and interventional techniques used for HCR and OPCAB were performed per protocol and have been previously published [9] . In short, HCR was performed on aspirin without a loading dose of clopidogrel. The femoral arterial sheath was placed prior to surgery; take-down of the left internal mammary artery (LIMA) was performed using a robotic system (Da Vinci Surgical System; Intuitive Surgical, Mountain View, CA, USA) and thoracic access was obtained by mini-thoracotomy. For patients undergoing OPCAB, the procedure was performed through conventional median sternotomy with the use of the LIMA and other arterial and vein graft conduits. Coronary arteriotomy and bypass graft anastomosis in both groups were performed without the use of cardiopulmonary bypass, and without the use of intracoronary shunts. The use of drug-eluting or bare-metal coronary stents as well as the duration of dual antiplatelet therapy were left at the discretion of the operators.
End-points
The primary end-point was to compare peak serum release of cardiac troponin I (cTnI) assessed after 24 h as an indicator for myocardial injury. This time window was chosen since it takes 24 h for cTnI to reach its peak serum level [10] . Secondly, we assessed postoperative length of stay, procedural complications (renal failure, postoperative atrial fibrillation, prolonged ventilation, infection at the access site, and reoperation) and a composite outcome of death, MI and repeat revascularization at 30 days and 1 year. Death was defined as all reported/documented deaths of any cause; myocardial infarction (MI) included procedure-related and spontaneous MI. Procedure-related MI was defined as ≥5 times the upper limit of normal of cardiac markers and new Q-waves on electrocardiography. Repeat revascularization involved any re-PCI or redo-CABG during follow-up.
Statistical analysis
Patients were compared based on the use of HCR or OPCAB. Comparisons between continuous variables were reported as median and interquartile range (IQR) and compared using the Wilcoxon rank-sum test. Discrete variables were reported as percent and compared using the Pearson χ 2 or exact test. Multivariable linear regression analysis was used to adjust for differences in baseline characteristics that may have influenced cardiac marker release. Adjustment variables included age, preoperative creatinine level, ejection fraction, total operating time, STS score and SYNTAX score. Linear regression assumptions, including normality and linearity, were assessed. Since postoperative cardiac marker release was not normally distributed, we applied a natural logarithm function transformation for the most appropriate fit. These natural logs of the cTnI values were used instead of the original raw values for our multivariable analysis. All reported P-values were two-sided, and values of <0.05 were considered statistically significant. All analyses were performed using IBM SPSS version 20.0.
RESULTS
Clinical and procedural characteristics
A total of 65 consecutive patients underwent elective HCR (n = 33) or OPCAB (n = 32). Baseline, procedural and follow-up data were obtained for all study participants. The clinical and angiographic characteristics are displayed in Table 1 . While patients undergoing HCR patients were less frequently female and had less hypertension, and no differences were seen in other comorbidities and medications. Moreover, the STS and the EuroSCORE risk scores as well as the lesion-specific SYNTAX score were all similar. Compared with OPCAB, total operating time (measured from time from incision to closure) was longer in the HCR group (365 vs 264 min, P <0.0001). In the OPCAB group, revascularization was performed with bypass conduits placed on a median of three vessels (25th-75th percentile: 2-3). In the HCR group, besides LIMA-to-LAD grafting, drug-eluting stents were used to perform PCI of non-LAD lesions in the majority of patients (75.8%), and the total stent length was 23.0 mm (95% confidence interval: 18.0-40.5 mm). Extubation in the operating room was more frequently performed in patients who underwent HCR (69.7 vs 25.0%, P <0.0001).
Post-procedural cardiac troponin I release
Although post-procedural measured cardiac troponin was elevated in all patients, the magnitude of cTnI elevation differed between the two groups, as illustrated in Fig. 1 . The median (and IQR) release of cTnI as a ratio of the upper reference level of normal was 3.5 (0.8-9.1) for patients after HCR, and 12.8 (6.9-21.8) for patients following OPCAB (P = 0.001). After adjusting for the aforementioned covariates, HCR was associated, on average, with cTnI less than half (46%) compared with CABG (P <0.0001).
Procedural complications and recovery
As given in Table 2 , there was a lower incidence of procedural complications (15.2 vs 34.4%, P = 0.072) in the HCR group, mainly due to less postoperative atrial fibrillation (12.1 vs 25.0%). Additionally, post-procedural recovery was faster in the HCR group, as illustrated by a shorter length of hospital stay in this group (median stay: 4 days, 25th-75th percentile: 3.25-7.00 vs 7 days, 25th-75th percentile: 4.5-9.0; P = 0.010).
Clinical outcomes at 30-day and 1-year follow-up
Clinical outcomes for the composite outcome of death, MI and repeat revascularization were similar between the two groups, both at the 30-day as well as at the 1-year follow-up (3.0 vs 3.1% and 9.1 vs 6.2%, respectively). Events that occurred within the first 30 days included 1 death in the HCR group due to acute stent thrombosis, and 1 death in the OPCAB group during reoperation for bleeding complications. At 1 year, 3 patients required repeat revascularization (HCR = 2, OPCAB = 1), and 1 patient in the OPCAB group suffered from an MI.
DISCUSSION
The benefits of coronary revascularization either by OPCAB or HCR may partially be offset by new myocardial injury caused by the intervention itself. In this study, we demonstrated that cTnI when measured at postoperative day 1 is lower in patients undergoing one-sitting HCR, than in those undergoing OPCAB. HCR remained associated with lower cardiac marker release after adjustment for factors that influence myocardial injury during surgery. A prior study by Kon et al. [11] (n = 45) also found lower troponin I levels on Day 1 in elective patients undergoing samesitting HCR compared with OPCAB (1.4 ± 0.7 vs 2.8 ± 2.6 ng/ml, P ≤0.03). Additionally, they showed in blood samples drawn from the aorta and coronary sinus directly at case completion that ischaemia (myoglobin) and inflammation (interleukin 8) markers were lower in patients who underwent HCR compared with OPCAB. Our findings together with those found by Kon et al. [11] are interesting since they suggest that patients who undergo HCR have less procedure-related myocardial necrosis compared with patients who undergo OPCAB. Although speculative, this difference may be the result of less myocardial tissue damage due to less manipulation of the heart and less need for suturing since fewer grafts are placed following HCR. Prior studies have shown that both manipulation of the heart, the use of intracoronary Figure 1 : Distribution of cardiac troponin I release displayed in scatter and box-and-whisker plots measured 24 h after hybrid coronary revascularization (HCR) and off-pump coronary artery bypass (OPCAB) surgery. URL: upper reference level. shunts, and suture placement have been associated with periprocedural myocardial injury after surgery [12] [13] [14] . It is less clear whether HCR would also have different effects on other factors that have been associated with cardiac marker release during cardiac surgery, such as microvascular events related to reperfusion, myocardial injury induced by oxygen free radical generation, coronary dissection and insufficient myocardial reperfusion due to incomplete revascularization [12] [13] [14] . The value of measuring cardiac biomarker release after coronary revascularization is undisputed, since it helps identify those patients in whom cardiac damage occurred and who could benefit from prolonged monitoring in an intensive or coronary care unit, to reduce the risk of postoperative complications, as well as in-hospital death [15, 16] . Although various cardiac markers can be used, cTnI and T have replaced creatine kinase-MB as the gold standard for biochemical diagnosis of myocardial injury as well as risk stratification [17] . As such, patients with normal preoperative cTnI values who have an increase of these values after revascularization are indicative of myocardial necrosis, and also imply that an increase in the magnitude of biomarker concentrations is related to an increasingly worse prognosis [18, 19] . Despite the lack of studies on the value of cardiac markers in HCR, it can be assumed that elevated cTnI can also be used for risk assessment in those patients similarly to those undergoing PCI or CABG. Although myocardial injury seems to be less after HCR, and it is therefore tempting to postulate that HCR may be an attractive alternative to OPCAB for selected patients, this conclusion should be viewed as premature as it is unknown whether lower cTnI release also leads to better clinical outcomes in HCR compared with OPCAB. It could very well be that a different threshold for cardiac marker release should be used for HCR than for OPCAB and on-pump CABG [20] . Further study to assess cardiac marker release after HCR is not only important for prognostic reasons, but also to determine a meaningful cut-off value for the definition of MI related to HCR, which in turn can be used as an end-point in clinical trials. Presumably, the definition for perioperative MI after HCR should probably also include electrocardiographic changes similar to the CABG criteria and not solely rely on an arbitrary cut-off for cardiac marker release as is done in PCI.
Given the trend in surgery towards more minimally invasive approaches compared with conventional open techniques, as well as promising results from specialized centres, HCR will likely become a more commonly applied approach for coronary revascularization in the future. Our study provides insight into the pattern of myocardial injury following HCR compared with OPCAB. To better serve our patients who may be suitable candidates for HCR, further study is warranted to identify specific causes for troponin release, the prognostic value, as well as cut-off values for the use of definitions for periprocedural MI after HCR.
Limitations
The findings of our study were based on a small, non-randomized, observational cohort of patients undergoing HCR in a singlecentre US hospital. As such, our findings are mainly hypothesis generating and require confirmation in larger, preferably randomized studies. Since cardiac markers were measured only once at 24 h after surgery, we could not calculate an integrated area under the curve analysis, which could have provided additional information on the time course of cTnI release as well as the total amount of cTnI released following the procedure. However, prior research has shown that the additional prognostic value of a kinetic analysis of cTnI release is limited compared with a single 24-h measurement after cardiac surgery [21] . Finally, due to our limited sample size, we could not reliably assess the relationship between cTnI and clinical outcomes following HCR.
CONCLUSIONS
cTnI release is significantly lower after one-stage HCR compared with off-pump surgical revascularization for patients with multivessel coronary disease and normal baseline cardiac markers. After adjustment, HCR remained associated with lower cardiac marker release.
